AI
ICPT

ArchPoint Investors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

ArchPoint Investors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-750
Closed -$84K – 139
2019
Q1 		$84K Buy
+750
New +$81.9K 0.03% 99

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ArchPoint Investors's ICPT Position: Q2 2019 in Review

ArchPoint Investors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2019, closing a stake of 750 shares — an estimated $84K sold.

ArchPoint Investors first reported a position in ICPT in Q1 2019 and held it in 1 quarter. The position peaked at $84K in Q1 2019. 196 funds tracked by Wall St. Rank hold ICPT as of Q2 2019.

  • ArchPoint Investors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • ArchPoint Investors sold 750 Intercept Pharmaceuticals, Inc. shares in Q2 2019, an estimated $84K.
  • ArchPoint Investors first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • ArchPoint Investors's Intercept Pharmaceuticals, Inc. position peaked at $84K in Q1 2019.
  • 196 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2019.

Based on ArchPoint Investors's 13F filing for Q2 2019, filed 26 Jul 2019.